Nobilis Health Corp.

Nobilis Health Corp.

NRTSF
Nobilis Health Corp.US flagOther OTC
0.00
USD
- -
- -
78.00Market Cap
2003 Y
2004 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
TTM
Revenue per Share
0.12
0.11
2.39
3.08
1.79
0.66
0.43
0.59
0.85
1.81
3.42
3.74
3.85
3.65
Basic EPS, GAAP
-0.22
-0.1
-0.51
-7.5
-0.75
-0.26
-0.07
0.03
0.04
0.14
0.76
0.08
0.05
0.02
Free Cash Flow per Basic Share
-0.06
-0.09
1.31
1.56
0.65
-0.22
-0.01
0.13
0.06
0.04
0.03
-0.05
0.27
0.1
Dividend per Share
- -
- -
0.6
0.99
0.05
- -
0.04
0.08
0.12
- -
- -
- -
- -
- -
Book Value per Share
-0.2
-0.24
-0.51
-8.99
-9.74
-7.46
-4.27
-3.98
-3.8
-2.86
-1.28
-1.03
-0.97
-1
Tangible Book Value per Share
-0.12
-0.13
-0.47
0.37
0.58
0.4
0.11
0.19
0.37
0.5
1.04
0.79
0.2
0.14
Basic Weighted Avg Shares
31
36
14
14
14
19
33
35
37
47
67
76
78
78
Sales/Revenue/Turnover
4
4
33
43
25
12
14
21
31
84
229
286
300
285
Operating Margin (%)
-177.11
-75.46
64.77
39.24
9.5
-55.63
13.95
25.76
14.45
24.22
15.36
3.38
8.24
8.02
Depreciation Expense
- -
- -
1
2
1
1
1
1
1
2
5
9
12
16
Net Income, GAAP
-7
-4
3
-104
-10
-5
-2
1
1
7
51
6
4
2
Effective Tax Rate (%)
- -
- -
28.12
- -
- -
- -
- -
- -
- -
- -
- -
38.72
55.84
60.7
Profit Margin (%)
-192.47
-93.59
9.6
-243.59
-41.67
-40.36
-15.13
5.74
4.55
8
22.18
2.26
1.27
0.58
Working Capital
-4
-5
15
10
8
5
4
7
9
24
64
98
98
97
LT Debt
- -
1
- -
- -
- -
- -
- -
2
- -
11
38
78
126
127
Total Equity
-4
-5
142
22
10
9
6
9
16
65
134
142
198
190
Return on Invested Capital (%)
- -
- -
22.21
- -
- -
- -
- -
69.37
34.7
40.19
- -
2.97
3.92
3.2
Return on Capital (%)
- -
- -
151.06
- -
- -
- -
- -
2.08
3.03
5.61
- -
-56.26
-0.06
-1.42
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Dec'17
Mar'18
Jun'18
ST Debt
11
14
13
LT Borrowings
113
115
116
LT Finance Leases
13
12
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
78
78
78
Market Capitalization
105
129
94

Working Capital

FRC

in mil. unless spec.
Dec'17
Mar'18
Jun'18
Total Current Assets
185
175
178
Cash, Cash Equivalents & STI
23
23
17
Accounts Receivable, Net
145
133
144
Inventories
3
3
3
Total Current Liabilities
87
80
80
Payables & Accruals
65
54
55
ST Debt
11
14
13
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.45%
106.77%
39%
Free Cash Flow
-360.2%
-189.76%
-633.35%
Net Income, GAAP
-283.06%
184.16%
-41.12%
Sales/Revenue/Turnover
42.09%
84.25%
4.89%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
51
62
71
102
286
2017
68
80
65
87
300
2018
64
69
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-0.07
0.06
-0.04
0.12
0.08
2017
-0.03
0.02
0.01
0.05
0.05
2018
-0.05
0.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Patrick Yoder
Full Time Employees
700
Sector
Healthcare
Industry
Medical - Care Facilities
Address
Houston Canada
IPO Date
Nov 7, 2011
Business
Nobilis Health Corp. (NRTSF) operates as a healthcare services company focused on providing surgical and ancillary medical services through a network of ambulatory surgery centers and specialty clinics. The company offers a range of core products and services including outpatient surgical procedures in areas such as orthopedics, pain management, gastroenterology, and plastic surgery; ancillary services encompassing anesthesia, imaging diagnostics, and physical therapy; and patient financing options to support elective procedures. It primarily serves patients seeking non-emergency ambulatory care, targeting markets in the United States with operations concentrated in Texas and surrounding regions; founded in 2014 and headquartered in Vancouver, Canada, with key facilities managed through subsidiaries. In recent developments within the last two years, Nobilis Health underwent significant operational restructuring including a shift from aggressive clinic expansion to cost optimization and facility rationalization following financial challenges; it also navigated creditor protection proceedings in 2020 leading to substantial debt reduction and equity recapitalization, enabling a stabilized platform for growth; no major new partnerships, acquisitions, or product launches were reported in 2024-2025.